New insights into mechanisms of resistance to microtubule inhibitors

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 2, 2011, Pages 164-171

  Ganguly, Anutosh ^a   Cabral, Fernando ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cell motility; Microtubule detachment; Microtubule dynamics; Mitosis; Paclitaxel; Tubulin

Indexed keywords

COLCHICINE; DEMECOLCINE; EPOTHILONE A; EPOTHILONE DERIVATIVE; KINESIN; MICROTUBULE ASSOCIATED PROTEIN; MITOTIC CENTROMERE ASSOCIATED KINESIN; PACLITAXEL; STATHMIN; TETRACYCLINE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL ACTIVITY; CELL ADHESION; CELL MOTILITY; CENTROSOME; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROTUBULES; NEOPLASMS; TUBULIN MODULATORS;

EID: 79960654509     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.06.001     Document Type: Review

References (100)

1. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 2007, 8:379-393.
2. Blagosklonny M.V. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007, 6:70-74.
3. Schwartz E.L. Antivascular actions of microtubule-binding drugs. Clin. Cancer Res. 2009, 15:2594-2601.
4. Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 2010, 13:16-28.
5. Wiese C., Zheng Y. Microtubule nucleation: gamma-tubulin and beyond. J. Cell Sci. 2006, 119:4143-4153.
6. Mitchison T., Kirschner M.W. Dynamic instability of microtubules. Nature 1984, 312:237-242.
7. Jordan M.A., Wilson L. Use of drugs to study role of microtubule assembly dynamics in living cells. Methods Enzymol. 1998, 298:252-276.
8. Kirschner M., Mitchison T. Beyond self-assembly: from microtubules to morphogenesis. Cell 1986, 45:329-342.
9. Wollman R., Cytrynbaum E.N., Jones J.T., Meyer T., Scholey J.M., Mogilner A. Efficient chromosome capture requires a bias in the 'search-and-capture' process during mitotic-spindle assembly. Curr. Biol. 2005, 15:828-832.
10. Cassimeris L., Pryer N.K., Salmon E.D. Real-time observation of microtubule dynamic instability in living cells. J. Cell Biol. 1988, 107:2223-2231.
11. Honore S., Kamath K., Braguer D., Horwitz S.B., Wilson L., Briand C., Jordan M.A. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res. 2004, 64:4957-4964.
12. Panda D., DeLuca K., Williams D., Jordan M.A., Wilson L. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9313-9318.
13. Yvon A.M., Wadsworth P., Jordan M.A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 1999, 10:947-959.
14. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. 2004, 4:253-265.
15. Cabral F. Mechanisms of resistance to drugs that interfere with microtubule assembly. Cancer Drug Discovery and Development: The Role of Microtubules in Cell Biology, Neurobiology, and Oncology 2008, 337-356. Humana Press, Totowa, NJ. A.T. Fojo (Ed.).
16. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist. Updat. 2001, 3:1-6.
17. Orr G.A., Verdier-Pinard P., McDavid H., Horwitz S.B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22:7280-7295.
18. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B., Poy G., Sackett D., Nicolaou K.C., Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2904-2909.
19. Giannakakou P., Sackett D.L., Kang Y.-K., Zhan Z., Buters J.T.M., Fojo T., Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 1997, 272:17118-17125.
20. Wang Y., O'Brate A., Zhou W., Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005, 4:1847-1853.
21. Gonzalez-Garay M.L., Chang L., Blade K., Menick D.R., Cabral F. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J. Biol. Chem. 1999, 274:23875-23882.
22. Hari M., Loganzo F., Annable T., Tan X., Musto S., Morilla D.B., Nettles J.H., Snyder J.P., Greenberger L.M. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 2006, 5:270-278.
23. Hari M., Wang Y., Veeraraghavan S., Cabral F. Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol. Cancer Ther. 2003, 2:597-605.
24. He L., Yang C.H., Horwitz S.B. Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther. 2001, 1:3-10.
25. Kavallaris M., Tait A.S., Walsh B.J., He L., Horwitz S.B., Norris M.D., Haber M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001, 61:5803-5809.
26. Liaw T.Y., Salam N.K., McKay M.J., Cunningham A.M., Hibbs D.E., Kavallaris M. Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions. Mol. Cancer Ther. 2008, 7:3150-3159.
27. Minotti A.M., Barlow S.B., Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J. Biol. Chem. 1991, 266:3987-3994.
28. Poruchynsky M.S., Kim J.H., Nogales E., Annable T., Loganzo F., Greenberger L.M., Sackett D.L., Fojo T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry 2004, 43:13944-13954.
29. Schibler M., Cabral F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α- and β-tubulin. J. Cell Biol. 1986, 102:1522-1531.
30. Verrills N.M., Flemming C.L., Liu M., Ivery M.T., Cobon G.S., Norris M.D., Haber M., Kavallaris M. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem. Biol. 2003, 10:597-607.
31. Wang Y., Veeraraghavan S., Cabral F. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid. Biochemistry 2004, 43:8965-8973.
32. Cabral F., Brady R.C., Schibler M.J. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann. N. Y. Acad. Sci. 1986, 466:745-756.
33. Cabral F. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J. Cell Biol. 1983, 97:22-29.
34. Whitfield C., Abraham I., Ascherman D., Gottesman M.M. Transfer and amplification of a mutant β-tubulin gene results in colcemid dependance: use of the transformant to demonstrate regulation of β-tubulin subunit levels by protein degradation. Mol. Cell. Biol. 1986, 6:1422-1429.
35. Barlow S.B., Gonzalez-Garay M.L., Cabral F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J. Cell Sci. 2002, 115:3469-3478.
36. Achiwa H., Sato S., Shimizu S., Maeda H., Niimi T., Takahashi T., Ueda R., Mitsudomi T. Analysis of beta-tubulin gene alteration in human lung cancer cell lines. Cancer Lett. 2003, 201:211-216.
37. de Castro J., Belda-Iniesta C., Cejas P., Casado E., Fresno Vara J.A., Hardisson D., Sanchez J.J., Feliu J., Ordonez A., Nistal M., Gonzalez-Baron M. New insights in beta-tubulin sequence analysis in non-small cell lung cancer. Lung Cancer 2003, 41:41-48.
38. Hasegawa S., Miyoshi Y., Egawa C., Ishitobi M., Tamaki Y., Monden M., Noguchi S. Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int. J. Cancer 2002, 101:46-51.
39. Maeno K., Ito K., Hama Y., Shingu K., Kimura M., Sano M., Nakagomi H., Tsuchiya S., Fujimori M. Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett. 2003, 198:89-97.
40. Sale S., Sung R., Shen P., Yu K., Wang Y., Duran G.E., Kim J.H., Fojo T., Oefner P.J., Sikic B.I. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol. Cancer Ther. 2002, 1:215-225.
41. Tsurutani J., Komiya T., Uejima H., Tada H., Syunichi N., Oka M., Kohno G., Fukuoka M., Nakagawa K. Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer 2002, 35:11-16.
42. Urano N., Fujiwara I., Hasegawa S., Miyoshi Y., Noguchi S., Takiguchi S., Yasuda T., Yano M., Monden M. Absence of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer 2003, 6:108-112.
43. Berrieman H.K., Lind M.J., Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy?. Lancet Oncol. 2004, 5:158-164.
44. McDaid H.M., Mani S., Shen H.J., Muggia F., Sonnichsen D., Horwitz S.B. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin. Cancer Res. 2002, 8:2035-2043.
45. Yee K.W., Hagey A., Verstovsek S., Cortes J., Garcia-Manero G., O'Brien S.M., Faderl S., Thomas D., Wierda W., Kornblau S., Ferrajoli A., Albitar M., McKeegan E., Grimm D.R., Mueller T., Holley-Shanks R.R., Sahelijo L., Gordon G.B., Kantarjian H.M., Giles F.J. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2005, 11:6615-6624.
46. Yin S., Bhattacharya R., Cabral F. Human mutations that confer paclitaxel resistance. Mol. Cancer Ther. 2010, 9:327-335.
47. Ong V., Liem N.L., Schmid M.A., Verrills N.M., Papa R.A., Marshall G.M., Mackenzie K.L., Kavallaris M., Lock R.B. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J. Pharmacol. Exp. Ther. 2008, 324:434-442.
48. Luduena R.F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol. 1998, 178:207-275.
49. Sullivan K.F. Structure and utilization of tubulin isotypes. Annu. Rev. Cell Biol. 1988, 4:687-716.
50. Leandro-Garcia L.J., Leskela S., Landa I., Montero-Conde C., Lopez-Jimenez E., Leton R., Cascon A., Robledo M., Rodriguez-Antona C. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010, 67:214-223.
51. Miller L.M., Xiao H., Burd B., Horwitz S.B., Angeletti R.H., Verdier-Pinard P. Methods in tubulin proteomics. Methods Cell Biol. 2010, 95:105-126.
52. Haber M., Burkhart C.A., Regl D.L., Madafiglio J., Norris M.D., Horwitz S.B. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem. 1995, 270:31269-31275.
53. Jaffrezou J.P., Dumontet C., Derry W.B., Duran G., Chen G., Tsuchiya E., Wilson L., Jordan M.A., Sikic B.I. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol. Res. 1995, 7:517-527.
54. Kavallaris M., Kuo D.Y.S., Burkhart C.A., Regl D.L., Norris M.D., Haber M., Horwitz S.B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 1997, 100:1282-1293.
55. Ranganathan S., Benetatos C.A., Colarusso P.J., Dexter D.W., Hudes G.R. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer 1998, 77:562-566.
56. Blade K., Menick D.R., Cabral F. Overexpression of class I, II, or IVb β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J. Cell Sci. 1999, 112:2213-2221.
57. Hari M., Yang H., Zeng C., Canizales M., Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil. Cytoskeleton 2003, 56:45-56.
58. Yang H., Cabral F. Heightened sensitivity to paclitaxel in class IVa β-tubulin transfected cells is lost as expression increases. J. Biol. Chem. 2007, 282:27058-27066.
59. Bhattacharya R., Cabral F. A ubiquitous β-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol. Biol. Cell 2004, 15:3123-3131.
60. Yang H., Ganguly A., Yin S., Cabral F. Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. Cytoskeleton (Hoboken) 2011, 68:175-187.
61. Bhattacharya R., Cabral F. Molecular basis for class V β-tubulin effects on microtubule assembly and paclitaxel resistance. J. Biol. Chem. 2009, 284:13023-13032.
62. Olmsted J.B. Non-motor microtubule-associated proteins. Curr. Opin. Cell Biol. 1991, 3:52-58.
63. Sloboda R.D., Dentler W.L., Rosenbaum J.L. Microtubule-associated proteins and the stimulation of tubulin assembly in vitro. Biochemistry 1976, 15:4497-4505.
64. Barlow S.B., Gonzalez-Garay M.L., West R.R., Olmsted J.B., Cabral F. Stable expression of heterologous microtubule associated proteins in Chinese hamster ovary cells: evidence for differing roles of MAPs in microtubule organization. J. Cell Biol. 1994, 126:1017-1029.
65. Spicakova T., O'Brien M.M., Duran G.E., Sweet-Cordero A., Sikic B.I. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol. Cancer Ther. 2010, 9:2970-2981.
66. Wang X.M., Peloquin J.G., Zhai Y., Bulinski J.C., Borisy G.G. Removal of MAP4 from microtubules in vivo produces no observable phenotype at the cellular level. J. Cell Biol. 1996, 132:345-357.
67. Cassimeris L., Spittle C. Regulation of microtubule-associated proteins. Int. Rev. Cytol. 2001, 210:163-226.
68. Howard J., Hyman A.A. Microtubule polymerases and depolymerases. Curr. Opin. Cell Biol. 2007, 19:31-35.
69. Howell B., Larsson N., Gullberg M., Cassimeris L. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. Mol. Biol. Cell 1999, 10:105-118.
70. Martello L.A., Verdier-Pinard P., Shen H.-J., He L., Torres K., Orr G.A., Horwitz S.B. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res. 2003, 63:1207-1213.
71. Iancu C., Mistry S.J., Arkin S., Wallenstein S., Atweh G.F. Effects of stathmin inhibition on the mitotic spindle. J. Cell Sci. 2001, 114:909-916.
72. Alli E., Bash-Babula J., Yang J.-M., Hait W.N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002, 62:6864-6869.
73. Moore A., Wordeman L. The mechanism, function and regulation of depolymerizing kinesins during mitosis. Trends Cell Biol. 2004, 14:537-546.
74. Desai A., Verma S., Mitchison T.J., Walczak C.E. Kin I kinesins are microtubule-destabilizing enzymes. Cell 1999, 96:69-78.
75. Ganguly A., Yang H., Cabral F. Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to Paclitaxel. Mol. Cancer Ther. 2011, 10:929-937.
76. Goncalves A., Braguer D., Kamath K., Martello L., Briand C., Horwitz S., Wilson L., Jordan M.A. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11737-11742.
77. Ganguly A., Yang H., Cabral F. Paclitaxel dependent cell lines reveal a novel drug activity. Mol. Cancer Ther. 2010, 9:2914-2923.
78. Yang H., Ganguly A., Cabral F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J. Biol. Chem. 2010, 285:32242-32250.
79. Bhattacharya R., Yang H., Cabral F. Class V β-tubulin alters dynamic instability and stimulates microtubule detachment from centrosomes. Mol. Biol. Cell 2011, 22:1025-1034.
80. Civelekoglu-Scholey G., Scholey J.M. Mitotic force generators and chromosome segregation. Cell. Mol. Life Sci. 2010, 67:2231-2250.
81. Mastronarde D.N., McDonald K.L., Ding R., McIntosh J.R. Interpolar spindle microtubules in PTK cells. J. Cell Biol. 1993, 123:1475-1489.
82. Tulu U.S., Rusan N.M., Wadsworth P. Peripheral, non-centrosome-associated microtubules contribute to spindle formation in centrosome-containing cells. Curr. Biol. 2003, 13:1894-1899.
83. Burbank K.S., Groen A.C., Perlman Z.E., Fisher D.S., Mitchison T.J. A new method reveals microtubule minus ends throughout the meiotic spindle. J. Cell Biol. 2006, 175:369-375.
84. Yang G., Houghtaling B.R., Gaetz J., Liu J.Z., Danuser G., Kapoor T.M. Architectural dynamics of the meiotic spindle revealed by single-fluorophore imaging. Nat. Cell Biol. 2007, 9:1233-1242.
85. Goshima G., Kimura A. New look inside the spindle: microtubule-dependent microtubule generation within the spindle. Curr. Opin. Cell Biol. 2010, 22:44-49.
86. Srayko M., O'toole E.T., Hyman A.A., Muller-Reichert T. Katanin disrupts the microtubule lattice and increases polymer number in C. elegans meiosis. Curr. Biol. 2006, 16:1944-1949.
87. Buster D., McNally K., McNally F.J. Katanin inhibition prevents the redistribution of gamma-tubulin at mitosis. J. Cell Sci. 2002, 115:1083-1092.
88. Ganguly A., Bhattacharya R., Cabral F. Cell cycle dependent degradation of MCAK: evidence against a role in anaphase chromosome movement. Cell Cycle 2008, 7:3187-3193.
89. Ems-McClung S.C., Walczak C.E. Kinesin-13s in mitosis: key players in the spatial and temporal organization of spindle microtubules. Semin. Cell Dev. Biol. 2010, 21:276-282.
90. Hartwig J., Italiano J.J. The birth of the platelet. J. Thromb. Haemost. 2003, 1:1580-1586.
91. Pasquier E., Honore S., Pourroy B., Jordan M.A., Lehmann M., Briand C., Braguer D. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005, 65:2433-2440.
92. Pourroy B., Honore S., Pasquier E., Bourgarel-Rey V., Kruczynski A., Briand C., Braguer D. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 2006, 66:3256-3263.
93. Ploussard G., Terry S., Maille P., Allory Y., Sirab N., Kheuang L., Soyeux P., Nicolaiew N., Coppolani E., Paule B., Salomon L., Culine S., Buttyan R., Vacherot F., de la Taille A. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010, 70:9253-9264.
94. Seve P., Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol. 2008, 9:168-175.
95. Kamath K., Wilson L., Cabral F., Jordan M.A. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 2005, 280:12902-12907.
96. Ganguly A., Yang H., Cabral F. Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration. Oncotarget 2011, 2:368-377.
97. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 2010, 7:455-465.
98. Dumontet C., Jordan M.A., Lee F.F. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther. 2009, 8:17-25.
99. Ferlini C., Raspaglio G., Mozzetti S., Cicchillitti L., Filippetti F., Gallo D., Fattorusso C., Campiani G., Scambia G. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res. 2005, 65:2397-2405.
100. Ferlini C., Raspaglio G., Cicchillitti L., Mozzetti S., Prislei S., Bartollino S., Scambia G. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?. Curr. Cancer Drug Targets 2007, 7:704-712.